- Home
- FPI vs FULC Comparison
FPI vs FULC Comparison
Compare FPI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPI
- FULC
- Stock Information
- Founded
- FPI 2013
- FULC 2015
- Country
- FPI United States
- FULC United States
- Employees
- FPI N/A
- FULC N/A
- Industry
- FPI Real Estate Investment Trusts
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- FPI Real Estate
- FULC Health Care
- Exchange
- FPI Nasdaq
- FULC Nasdaq
- Market Cap
- FPI 452.7M
- FULC 469.0M
- IPO Year
- FPI 2014
- FULC 2019
- Fundamental
- Price
- FPI $10.28
- FULC $9.05
- Analyst Decision
- FPI
- FULC Buy
- Analyst Count
- FPI 0
- FULC 7
- Target Price
- FPI N/A
- FULC $9.14
- AVG Volume (30 Days)
- FPI 350.3K
- FULC 441.1K
- Earning Date
- FPI 10-22-2025
- FULC 10-29-2025
- Dividend Yield
- FPI 2.33%
- FULC N/A
- EPS Growth
- FPI 229.01
- FULC N/A
- EPS
- FPI 1.21
- FULC N/A
- Revenue
- FPI $55,000,000.00
- FULC N/A
- Revenue This Year
- FPI N/A
- FULC N/A
- Revenue Next Year
- FPI N/A
- FULC N/A
- P/E Ratio
- FPI $8.53
- FULC N/A
- Revenue Growth
- FPI N/A
- FULC 2752.05
- 52 Week Low
- FPI $9.66
- FULC $2.32
- 52 Week High
- FPI $12.87
- FULC $9.89
- Technical
- Relative Strength Index (RSI)
- FPI 38.68
- FULC 52.93
- Support Level
- FPI $10.11
- FULC $8.45
- Resistance Level
- FPI $10.66
- FULC $9.84
- Average True Range (ATR)
- FPI 0.17
- FULC 0.59
- MACD
- FPI -0.01
- FULC -0.09
- Stochastic Oscillator
- FPI 25.42
- FULC 38.54
About FPI Farmland Partners Inc.
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.